Fibrinolysis is regulated, in part, by a balance between tissue-type plasminogen activator (tPA) and its specific, rapidly acting inhibitor, plasminogen activator inhibitor (PAI-1). PAI-1 synthesis occurs in a number of tissues including the vascular endothelial cell and is regulated via a complex process involving multiple factors. Abnormal plasma levels of PAI-1 have been associated with a variety of thromboembolic disorders in man. The studies outlined in this proposal aim to determine the structure of the human PAI-1 gene, characterize the regulation of PAI-1 gene expression at the molecular level, investigate the relationship between PAI-1 structure and function, and begin to study the molecular genetic basis of hereditary abnormalities in PAI-1. In preliminary studies, full-length human PAI-1 cDNA has been isolated from a lambda gt11 cDNA library and its complete sequence determined. The human PAI-1 gene has been localized to chromosome 7. The PAI-1 sequence shows extensive homology to other members of the serine protease inhibitor (SERPIN) supergene family. Preliminary studies of PAI-1 gene regulation show PAI-1 mRNA levels to be decreased approximately 10-fold in the presence of heparin and endothelial cell growth factor. If this heparin affect also occurs in vivo, this could add significantly to heparin's clinical affect by increasing tPA activity with a subsequent increase in fibrinolysis. In this proposal, these observations will be further characterized at the molecular level by quantitative mRNA studies and introduction of recombinant vectors to assess the role of specific regulatory sequences. The detailed structure of the human PAI-1 gene will be determined by the study of PAI-1 specific clones isolated from a recombinant human lambda phage genomic DNA library. Comparison of the deduced exon/intron structure and promotor sequences to those of other genes, particularly the SERPIN gene family, may have major implications for coordinate control of related genes and the evolution of gene families. One PAI-1 gene restriction length polymorphism (RFLP) has been identified in preliminary studies and additional ones will be sought. These tools can eventually be applied to genetic linkage analysis in families with hereditary thromboembolic disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL039137-01
Application #
3355743
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1987-07-01
Project End
1992-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Eitzman, D T; McCoy, R D; Zheng, X et al. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232-7
Eitzman, D T; Krauss, J C; Shen, T et al. (1996) Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87:4718-22
Eitzman, D T; Fay, W P; Lawrence, D A et al. (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95:2416-20
Fay, W P; Eitzman, D T; Shapiro, A D et al. (1994) Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 83:351-6
Lawrence, D A; Olson, S T; Palaniappan, S et al. (1994) Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 33:3643-8
Lawrence, D A; Berkenpas, M B; Palaniappan, S et al. (1994) Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 269:15223-8
Lawrence, D A; Olson, S T; Palaniappan, S et al. (1994) Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 269:27657-62
Naski, M C; Lawrence, D A; Mosher, D F et al. (1993) Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 268:12367-72
Fay, W P; Shapiro, A D; Shih, J L et al. (1992) Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729-33
Sherman, P M; Lawrence, D A; Yang, A Y et al. (1992) Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 267:7588-95

Showing the most recent 10 out of 13 publications